EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A

Ying Liu, Satoshi Yamazaki, Makoto Ojika iD

Molecules · 2023

DOI: 10.3390/molecules28062815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Ying Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan. Hauptthemen laut MEDLINE: Myxococcales, Depsipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hard-to-culture slightly halophilic myxobacterium “Paraliomyxa miuraensis” SMH-27-4 produces antifungal cyclodepsipeptide miuraenamide A (1). Herein, the region (85.9 kbp) containing the biosynthetic gene cluster (BGC) coding the assembly of 1 was identified and heterologously expressed in Myxococcus xanthus. A biosynthetic pathway proposed using in silico analysis was verified through the gene disruption of the heterologous transformant. In addition to the core polyketide synthase (PKS) and nonribosomal peptide synthase (NRPS) genes, tyrosine halogenase and O-methyltransferase genes participated in the biosynthesis of 1 as their gene-disrupted mutants produced a new congener, debromomiuraenamide A (4), and a previously isolated congener, miuraenamide E (3), respectively. Multigene disruption provided a heterologous mutant that produced 1 with the highest yield among the prepared mutants. When fed on 3-bromo-L-tyrosine, this mutant produced more 1 in the yield of 1.21 mg/L, which was 20 times higher than that produced by the initially prepared heterologous transformant. Although this yield was comparable to that of the original producer SMH-27-4 (1 mg/L), the culture time was 4.5 times shorter than that of SMH-27-4, indicating a five-fold efficiency in productivity. The results indicate the great potential of the miuraenamide BGC for the future contribution to drug development through logical gene manipulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyxococcalesDepsipeptidesAnti-Bacterial AgentsPolyketide SynthasesMultigene Family

Stichwörter der Autor:innen

Paraliomyxa miuraensisbiosynthesishalophilic myxobacteriaheterologous expressionmiuraenamide A

Substanzen

Anti-Bacterial Agentsmiuraenamide ADepsipeptidesPolyketide Synthases

Autor:innen und Institutionen

  • Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan.

ORCID-Profile: Makoto Ojika

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency

Zitieren

APA

Liu, Y., Yamazaki, S., & Ojika, M. (2023). Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A. Molecules. https://doi.org/10.3390/molecules28062815

Vancouver

Liu Y, Yamazaki S, Ojika M. Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A. Molecules. 2023. doi:10.3390/molecules28062815

BibTeX
@article{Liu2023,
  author = {Liu, Ying and Yamazaki, Satoshi and Ojika, Makoto},
  title = {Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28062815}
}
Kostenlos starten →